Lithium and kidney, 60 years later

Current Drug Safety

Volumn 6, Issue 5, 2011, Pages 291-303

  Raja, Michele ^a  

^a Centro Studi e Ricerche Gaetano Perusini   (Italy)

Author keywords

Bipolar disorder; Lithium; Side effects; Suicide; Treatment

Indexed keywords

ADENYLATE CYCLASE; AMILORIDE; AMINOPHYLLINE; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLYCOGEN SYNTHASE KINASE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LITHIUM; LITHIUM CARBONATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMA PROTEIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THIAZIDE DIURETIC AGENT;

AFFECTIVE PSYCHOSIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIARRHEA; DIURESIS; DOSAGE SCHEDULE COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERNATREMIA; HYPERPARATHYROIDISM; HYPOVOLEMIA; INTERSTITIAL NEPHRITIS; INTOXICATION; KIDNEY; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MOOD DISORDER; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NONHUMAN; POLYURIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SALURESIS; SIDE EFFECT; SINGLE DRUG DOSE; URINARY FREQUENCY; URINE VOLUME; VOMITING;

ANIMALS; ANTIMANIC AGENTS; DRUG MONITORING; HUMANS; KIDNEY DISEASES; LITHIUM COMPOUNDS; SEVERITY OF ILLNESS INDEX;

EID: 84855862052     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798918737     Document Type: Review

References (136)

1. Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158(5): 666-75.
2. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17(2): 149-73.
3. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162(10): 1805-19.
4. Angst J, Angst F, Gerber-Werder R, et al. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005; 9(3): 279-300.
5. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19(5): 427-34.
6. Adityanjee. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry 1995; 152(4): 648-9.
7. Timmer RT, Sands JM. Lithium Intoxication. J Am Soc Nephrol 1999; 10(3): 666-74.
8. Borkan SC. Extracorporeal therapies for acute intoxications. Crit Care Clin 2002; 18(2): 393-420.
9. De Oliveira JL, Da Silva Jr GB, de Abreu KL, et al. Lithium nephrotoxicity. Rev Assoc Med Bras 2010; 56(5): 600-6.
10. Okusa MD, Crystal LJ. Clinical manifestations and management of acute lithium intoxication. Am J Med 1994; 97(4): 383-9.
11. Trepiccione F. Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol 2010; 23 Suppl 16: S43-8.
12. Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5(5): 270-6.
13. Alexander MP, Farag YMK, Mittal BV, et al. Lithium toxicity: a double-edged sword. Kidney Int 2008; 73(2): 233-7.
14. Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20(3): 231-43.
15. Bichet DG. V2R Mutations and Nephrogenic Diabetes Insipidus. Prog Mol Biol Transl Sci 2009; 89: 15-29.
16. Forrest JN Jr, Cohen AD, Torretti J, et al. On the mechanism of lithiuminduced diabetes insipidus in man, and the rat. J Clin Invest 1974; 53(4): 1115-23.
17. Lenox RH, McNamara RK, Papke RL, et al. Neurobiology of lithium: an update. J Clin Psychiatry 1998; 59(Suppl 6): 37-47.
18. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10(5): 329-45.
19. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 21(6): 449-56.
20. Gabutti L, Gugger M, Marti HP. Impaired kidney function in lithium therapy. Ther Umsch 1998; 55(9): 562-4.
21. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997; 54(1): 9-13.
22. Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. Eur Psychiatry 2001; 16(4): 199-206.
23. Presne C, Fakhouri F, Noël LH, et al. Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 2003; 64(2): 585-92.
24. Bendz H. Kidney function in lithium treated patients. Acta Psychiar Scand 1983; 68(5): 303-24.
25. Le Roy V, Delmas Y, Verdoux H. Chronic renal complications induced by lithium. Encephale 2009; 35(6): 605-10.
26. Yasui M, Zelenin SM, Celsi G, et al. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol 1997; 272(4 Pt 2): F443-50.
27. Matsumura Y, Uchida S, Rai T, et al. Transcriptional regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol 1997; 8(6): 861-7.
28. Christensen BM, Zuber AM, Loffing J et al. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 2011; 22(2): 253-61.
29. Ge Y, Si J, Tian L, et al. Conditional ablation of glycogen synthase kinase 3β in postnatal mouse kidney. Lab Invest 2011; 91(1): 85-96.
30. Nielsen J, Kwon TH, Frøkiær J, et al. in rats is associated with loss of-ENaC regulation by aldosterone in CCD. Am J Physiol Renal Physiol 2006; 290(5): F1222-33.
31. Shirley DG, Walter SJ. Is lithium a useful tool in studies on renal sodium handling? J Nephrol 1995; 9: 126-32.
32. Thomsen K, Shirley DG. A hypothesis linking sodium, and lithium reabsorption in the distal nephron. Nephrol Dial Transplant 2006; 21(4): 869-80.
33. Marples D, Christensen S, Christensen EI, et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 1995; 95(4): 1838-45.
34. Marples D, Frokiaer J, Knepper MA, et al. Disordered water channel expression and distribution in acquired nephrogenic diabetes insipidus. Proc Assoc Am Physicians 1998; 110(5): 401-6.
35. Promeneur D, Kwon TH, Frokiaer J, et al. Vasopressin V(2)-receptordependent regulation of AQP2 expression in Brattleboro rats. Am J Physiol Renal Physiol 2000; 279(2): F370-82.
36. Walker RJ, Weggery S, Bedford JJ, et al. Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers. Kidney Int 2005; 67(1): 291-4.
37. + transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 2000; 279(3): F552-64.
38. Laursen UH, Pihaskaski-Maunsbach K, Kwon TH, et al. Changes of rat kidney AQP2, and Na, K-ATPase mRNA expression in lithiuminduced nephrogenic diabetes insipidus. Nephron Exp Nephrol 2004; 97(1): e1-e16.
39. Robben JH, Knoers NVAM, Deen PMT. Cell biological aspects of the vasopressin type-2 receptor, and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006; 291(2): F257-70.
40. Hoffert JD, Pisitkun T, Wang G, et al. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites. Proc Natl Acad Sci USA 2006; 103(18): 7159-64.
41. Bedford JJ, Leader JP, Jing R, et al. Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2008; 294(4): F812-20.
42. Li Y, Shaw S, Kamsteeg FJ, et al. Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 2006; 17(4): 1063-72.
43. Walker RG. Lithium nephrotoxicity. Kidney Int Suppl. 1993; 44: S93-8.
44. Rao R, Zhang MZ, Zhao M, et al. Lithium treatment inhibits renal GsK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 2005; 288(4): F642-9.
45. Kotnik P. Altered expression of COX-1, COX-2, and mPEGS in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 2005; 288(5): F1053-68.
46. 2, cAMP, and vasopressin in lithium-induced polyuria. Am J Physiol Regul Integr Comp Physiol 1988; 254(6 Pt 2): R863-9.
47. 2 inhibits water permeability at a post-cAMP site in rat terminal inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 1992; 262(2 Pt 2): F229-35.
48. Han JS, Maeda Y, Ecelbarger C, et al. Vasopressin-independent regulation of collecting duct water permeability. Am J Physiol Renal Fluid Electrolyte Physiol 1994; 266(1 Pt 2): F139-46.
49. +, and urea transport in rat inner medullary collecting duct. Am J Physiol Renal Physiol 2000; 279(2): F294-301.
50. 2 interaction with AVP: effect of AQP2 phosphorylation and distribution. Am J Physiol Renal Physiol 2000; 278(3): F338-94.
51. Allen HM, Jackson RL, Winchester MD, et al. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989; 149(5): 1123-6.
52. Zhang Y, Nelson RD, Carlson NG, et al. Potential role of purinergic signaling in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2009; 296(5): F1194-201.
53. Klein J, Gunn RB, Roberts BR, et al. Down-regulation of urea transporters in the renal inner medulla of lithium-fed rats. Kidney Int 2002; 61(3): 995-1002.
54. Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008; 3(5): 1324-31.
55. 2O transport in inner medullary collecting duct subsegment. Am J Physiol Renal Fluid Electrolyte Physiol 1987; 253(5 Pt 2): F823-32.
56. Star RA, Nonaguchi H, Balaban RS, et al. Calcium, and cyclic adenosine monophosphate as second messengers for vasopressin in the rat inner medullary collecting duct. J Clin Invest 1988; 81(6): 1879-88.
57. Christensen BM, Marples D, Kim YH, et al. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 2004; 286(4): C952-64.
58. Christensen BM, Kim YH, Kwon TH, et al. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 2006; 291(1): F39-48.
59. Kim YH, Kwon TH, Christensen BM, et al. Altered expression of renal acid-base transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 2003; 285(6): F1244-57.
60. Rojek A, Nielsen J, Brooks HL, et al. Altered expression of selected genes in kidney of rats with lithium-induced NDI. Am J Physiol Renal Physiol 2005; 288(6): F1276-89.
61. Félix P, Stoermann-Chopard C, Martin PY. Lithium and chronic kidney disease: a pathology which remains relevant. Rev Med Suisse 2010; 6(238): 448-52.
62. Kanfer A, Blondiaux I. Renal and metabolic complications of lithium. Nephrologie 2000; 21(2): 61-70.
63. Tran-Van D, Avargues P, Labadie P, et al. Intravenous ketoprofen for severe lithium-induced polyuria. Press Med 2005; 34(16 Pt 1): 1137-40.
64. Lam SS, Kjellstrand C. Emergency treatment of lithium-induced diabetes insipidus with nonsteroidal anti-inflammatory drugs. Ren Fail 1997; 19(1): 183-8.
65. Murray MD, Brater DC. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33: 435-65.
66. Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase-2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 2003; 64(11): 1328-34.
67. Frölich JC, Leftwich R, Ragheb M, et al. Indomethacin increases plasma lithium. Br Med J 1979; 1(6171): 1115-6.
68. Bravo R, Egger SS, Crespo S, et al. Lithium intoxication as a result of interaction with rofecoxib. Ann Pharmacother 2004; 38(7-8): 1189-93.
69. Ragheb M. The clinical significance of lithium-nonsteroidal antiinflammatory drug interactions. J Clin Psychopharmacol 1990; 10(5): 350-4.
70. Garty H, Palmer LG. Epithelial sodium channels: function, structure, and regulation. Physiol Rev 1997; 77(2): 359-96.
71. Battle D, von Riotte A, Gaviria M, et al. Amelioration of polyuria by amiloride in patients receiving long term therapy. New Engl J Med 1985; 312(7): 408-14.
72. Koston T, Forrest J. Treatment of severe lithium-induced polyuria with amiloride. Am J Psychiatry 1986; 143(12): 1563-68.
73. Finch CK, Kelley KW, Williams RB. Treatment of lithium-induced diabetes insipidus with amiloride. Pharmacotherapy 2003; 23(4): 546-50.
74. Rose SR, Klein Schwartz W, Oderda GM, et al. Lithium intoxication with acute renal failure and death. Drug Intell Clin Pharm 1988; 22(9): 691-4.
75. Dyson EH, Simpson D, Prescott LF, et al. Self-poisoning and therapeutic intoxication with lithium. Hum Toxicol 1987; 6(4): 325-9.
76. Lawler PG, Cove-Smith JR. Acute respiratory failure following lithium intoxication. A report of two cases. Anaesthesia 1986; 41(6): 623-7.
77. Lee YC, Lin JL, Lee SY, et al. Outcome of patients with lithium poisoning at a far-east poison center. Hum Exp Toxicol 2011; 30(7): 528-34.
78. Nascimento L, Rademacher DR, Hamburger R, et al. On the mechanism of lithium-induced renal tubular acidosis. J Lab Clin Med 1977; 89(3): 455-62.
79. Markowitz GS, Radhakrishnan J, Kambham N, et al. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11(8): 1439-48.
80. Hestbech J, Hansen HE, Amdisen A, et al. Chronic renal lesions following long term treatment with lithium. Kidney Int 1977; 12(3): 205-13.
81. Walker RG, Bennett WM, Davies BM, et al. Structural and functional effects of long-term lithium therapy. Kidney Int Suppl 1982; 11: S13-9.
82. Tuazon J, Casalino D, Syed E, et al. Lithium-associated kidney microcysts. Scient World J 2008; 31(8): 828-9.
83. Alexander F, Martin J: Nephrotic syndrome associated with lithium therapy. Clin Nephrol 1981; 15(5): 267-71.
84. Tamm VKK, Green J, Schwieger J, et al. Nephrotic syndrome and renal insufficiency associated with lithium therapy. Am J Kidney Dis 1996; 27(5): 715-20.
85. Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988; 84(5): 951-4.
86. Schou M. Effects of long-term lithium treatment on kidney function: an overview. J Psychiatr Res. 1988; 22(4): 287-90.
87. Schou M. Long-term treatment with lithium and renal function. A review and reappraisal. Encephale 1989; 15(5): 437-42.
88. von Knorring L, Wahlin A, Nystroem K, et al. Uraemia induced by long-term renal treatment. Lithium 1990; 1: 251-3.
89. Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993; 13(4): 276-9.
90. Kala GK, Mogri M, Weber-Shrikant E, et al. Lithium-induced membranous glomerulonephropathy in a pediatric patient. Pediatr Nephrol 2009; 24(11): 2267-9.
91. Jorgensen F, Larsen S, Spanager B, et al. Kidney function and quantitative histologic changes in patients on long-term lithium therapy. Acta Psychiatr Scand 1984; 70(5): 455-62.
92. Bendz H, Aurell M, Balldin J, et al. Kidney damage in long-term lithium patients: A cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9(9): 1250-4.
93. Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord 2010; 126(3): 436-40.
94. Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1-30 years. Acta Psychiatr Scand 1995; 91(1): 48-51.
95. Kehoe R. A cross-sectional study of glomerular function in 740 unselected lithium patients. Acta Psychiatr Scand 1994; 89(1): 68-71.
96. Walker R, Burrows G, Schweitzer I, et al. Renal function after 20 years of lithium therapy. Paper presented at the Congress CINP, Melbourne, 1996.
97. Aurell M, Svalander C, Wallin L, et al. Renal function and biopsy findings in patients on long-term lithium treatment. Kidney Int 1981; 20(5): 663-70.
98. Hansen HE. Renal toxicity of lithium. Drugs 1981; 22(6): 461-76.
99. Johnson GF, Hunt GE, Duggin GG, et al. Renal function and lithium treatment: initial and follow-up tests in manic-depressive patients. J Affect Disord 1984; 6(3-4): 249-63.
100. Johnson G. Lithium. Med J Austr 1984; 141(9): 595-601.
101. DePaulo J, Correa E, Sapir D. Renal function and lithium: A longtitudinal study. Am J Psychiatry 1986; 143(7): 892-5.
102. Jorkasky DK, Amsterdam JD, Oler J, et al. Lithium-induced renal disease: a prospective study. Clin Nephrol 1988; 30(6): 293-302.
103. Lokkegard H, Andersen N, Henriksen E, et al. Renal function in 153 manic depressive patients treated with lithium for more than five years. Acta Psychiatr Scand 1985; 71(4): 347-55.
104. Hetmar O, Brun C, Clemmesen L, et al. Lithium: Long-term effects on the kidney. II. Structural changes. J Psychiatr Res 1987; 21(3): 279-88.
105. Hetmar O, Povlsen UJ, Ladefoged J, et al. Lithium: long-term effects on the kidney. A prospective follow-up study ten years after kidney biopsy. Br J Psychiatry 1991; 158: 53-8.
106. Povlsen UJ, Hetmar O, Ladeforged J, et al. Kidney functioning during lithium treatment: a prospective study of patients treated with lithium for up ten years. Acta Psychiatr Scand 1992; 85(1): 56-60.
107. Lepkifker E, Sverdlik A, Iancu I, et al. Renal insufficiency in long-term lithium treatment. J Clin Psychiatry 2004; 65(6): 850-6.
108. Bendz H, Schön S, Attman PO, et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77(3): 219-24.
109. Bassilios N, Martel P, Godard V, et al. Monitoring of glomerular filtration rate in lithium-treated outpatients: an ambulatory laboratory database surveillance. Nephrol Dial Transplant 2008; 23(2): 562-5.
110. Janowsky DS, Soares J, Hatch JP, et al. Lithium effect on renal glomerular function in individuals with intellectual disability. J Clin Psychopharmacol 2009; 29(3): 296-9.
111. Johnson, G. Lithium: early development, toxicity, and renal function. Neuropsychopharmacology 1998; 19(3): 200-5.
112. Freeman MP, Freeman SA. Lithium: clinical consideration sin Internal Medicine. Am J Med 2006; 119(6): 478-81.
113. Bendz H, Sjödin I, Toss G, et al. Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240(6): 357-65.
114. Marcus WL. Lithium: a review of its pharmacokinetics, health effects, and toxicology. J Environ Pathol Toxicol Oncol 1994; 13(2): 73-9.
115. Breslau NA. Update on secondary forms of hyperparathyroidism. Am J Med Sci 1987; 294(2): 120-31.
116. Farres MT, Ronco P, Saadoun D, et al. Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 2003; 229(2): 570-4.
117. Nascimento AB, Mitchell DG, Zhang X, et al. Rapid MR imaging detection of renal cysts: age-based standards. Radiology 2001; 221(3): 628-32.
118. Anon. Drug treatments for bipolar disorder: maintenance, prevention and special situations. Drug Ther Bull 2005; 43: 33-7.
119. Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23(4): 331-49.
120. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care-clinical guideline 90. 2009. http://guidance.nice.org.uk/CG90/Guidance/pdf/English
121. Collins N, Barnes TRE, Shingleton-Smith A, et al. Standards of lithium monitoring in mental health trusts in the UK. BMC Psychiatry 2010; 10: 80.
122. Kelly CB, Cooper SJ. Toxic elevation of serum lithium concentration by nonsteroidal anti-inflammatory drugs. Ulster Med J 1991; 60(2): 240-2.
123. Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004; 52(5): 794-8.
124. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29(3): 172-91.
125. Mahli GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 2011; 25(4): 289-98.
126. Hetmar O, Brun C, Ladefoged J, et al. Long-term effects of lithium on the kidney: functional-morphological correlations. J Psychiatry Res 1989; 23(3-4): 285-97.
127. Singh LK, Nizamie, SH, Akhtar S, et al. Improving Tolerability of Lithium With a Once-Daily Dosing Schedule. Am J Ther 2011; 18(4): 288-91.
128. Muir A, Davidson R, Silverstone T, et al. Two regimens of lithium prophylaxis and renal function. Acta Psychiatr Scand 1989; 80(6): 579-83.
129. Abraham G, Delva N, Waldron J, et al. Lithium treatment: a comparison of once-and twice-daily dosing. Acta Psychiatr Scand 1992; 85(1): 65-9.
130. Abraham G, Waldrom JJ, Lawson JS. Are the renal effects of lithium modified by frequency of administration? Acta Psychiatr Scand 1995; 92(2): 115-8.
131. Jefferson JW. A clinician's guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry 2010; 71(9): 1153-7.
132. Duncan L, Heathcote J, Djurdjev O, et al. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant 2001; 16(5): 1042-6.
133. Morriss, R, Benjamin B. Lithium and eGFR: a new routinely available tool for the prevention of chronic kidney disease. Br J Psychiatry 2008; 193(2): 93-5.
134. National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. British Psychological Society & Gaskell, 2006.
135. Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use? Br J Psychiatry 2007; 191(12): 474-6.
136. Royal College of Physicians of Edinburgh. UK Consensus Conference on Early Chronic Kidney Disease. Royal College of Physicians of Edinburgh, 2007 (http://www.rcpe.ac.uk/Whats_New/consensusstatements/final-early-chronic-kidney-disease.pdf).